HC Wainwright Brokers Lift Earnings Estimates for Precigen

Precigen, Inc. (NASDAQ:PGEN) – Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Precigen in a report issued on Thursday, May 14th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.02 per share for the year, up from their prior estimate of ($0.02). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Precigen’s current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for Precigen’s FY2027 earnings at $0.34 EPS.

PGEN has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Citizens Jmp lifted their target price on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 14th. Wall Street Zen raised shares of Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research note on Thursday. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $11.00.

Precigen Trading Down 7.9%

Shares of PGEN opened at $4.07 on Tuesday. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -3.45 and a beta of 1.07. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. Precigen has a fifty-two week low of $1.28 and a fifty-two week high of $5.47. The firm has a 50 day moving average price of $3.87 and a 200-day moving average price of $4.08.

Precigen (NASDAQ:PGEN) last announced its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $23.25 million during the quarter, compared to analyst estimates of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%.

Insider Activity at Precigen

In related news, Director Randal J. Kirk sold 4,772,781 shares of Precigen stock in a transaction on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the transaction, the director directly owned 302,213 shares of the company’s stock, valued at $997,302.90. The trade was a 94.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 47.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Lansing Street Advisors purchased a new position in Precigen during the 3rd quarter valued at $1,800,000. Patient Capital Management LLC increased its position in Precigen by 62.6% during the 3rd quarter. Patient Capital Management LLC now owns 26,460,848 shares of the biotechnology company’s stock valued at $87,056,000 after purchasing an additional 10,192,107 shares during the period. Boxer Capital Management LLC purchased a new position in Precigen during the 3rd quarter valued at $2,796,000. Rafferty Asset Management LLC purchased a new position in Precigen during the 3rd quarter valued at $338,000. Finally, Rhumbline Advisers increased its position in Precigen by 8.9% during the 3rd quarter. Rhumbline Advisers now owns 215,769 shares of the biotechnology company’s stock valued at $710,000 after purchasing an additional 17,691 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.